CN2732243Y - Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule - Google Patents
Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule Download PDFInfo
- Publication number
- CN2732243Y CN2732243Y CNU2004200662494U CN200420066249U CN2732243Y CN 2732243 Y CN2732243 Y CN 2732243Y CN U2004200662494 U CNU2004200662494 U CN U2004200662494U CN 200420066249 U CN200420066249 U CN 200420066249U CN 2732243 Y CN2732243 Y CN 2732243Y
- Authority
- CN
- China
- Prior art keywords
- capsule
- enterococcus
- lactobacillus
- viable bacteria
- bacilli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The utility model belongs to the field of medicinal and pharmaceutical substances, particularly a live bifidobacterium, lactobacillus, enterococcus and bacillus cereus tetrad capsule. The capsule is composed of a visceral pharmaceutical mixture and a carrier capsule shell. The utility model is characterized in that the capsule shell comprises a capsule cap, a capsule body and a sealing layer which is arranged at the middle of the capsule shell. The manufacturing technique of the utility model is simple. Excipient such as admixture, etc. does not need to be used during manufacture. Instantaneous high heat and high voltage generated when tablets are formed can not be generated during manufacture of the bifidus tetrad capsule simultaneously, which can avoid large loss for viable bacteria count during manufacture (the process of tablets forming can lose completed viable bacteria count by 5-10 times). The cost is greatly decreased.
Description
Technical field:
This utility model belongs to the medical supplies field, relates in particular to bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four.
Background technology:
This capsule is a kind of mycopowder of four kinds of bacterium such as bacillus bifidus or a kind of microbial ecological agent for the treatment of intestinal tract disease of adjuvant of containing.Because it contains active bacteria, the technical scheme of tablet can cause a large amount of strains inactivation in preparation process in the prior art, is very significant so adopt capsule structure for the bifidoquater medicine of treatment intestinal tract disease.
Yet medicament capsule of the prior art generally all takes utricule to put into the structure that puts capsule cap behind the medicine.Existing capsule often makes capsule body cooperate pine with capsule cap in assembling and production and transport process, and medication person does not notice that slightly shedding will appear in medicine.In addition, capsule body and capsule cap will inevitably produce the gap on respective outer side edges, make and be contained in the influence that the interior medicine of capsule inevitably can be subjected to external atmosphere and place environment, external physical conditions such as the humidity of air, temperature can make ingredient produce physics or chemical change, influence the therapeutic efficiency of medicine.
Simultaneously, conventional capsule is that various different pharmaceuticals are placed in the same capsule simultaneously when using at present.No matter medicine is Powdered or graininess, that activity is not strong principal agent and accessory drugs are separated, because the physicochemical property difference of medicine, physics and chemical change take place easily, thereby pharmacological action is weakened, even the generation serious adverse, human body is worked the mischief, influence people's physical and mental health.
The purpose of this utility model provides bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, four kinds of active bacterias are housed in the capsule, it can make the strain of different physicochemical properties and pharmacological action be stored in respectively in not connected sealing coat or the combined type cavity, thereby avoids medicine of different nature to put the drug failure that causes altogether.Simultaneously,, strain and other accessory drugss are sealed in the sealant, thereby make this medicine keep active, realize the effect of treatment intestinal tract disease for guaranteeing pharmaceutically active.
Summary of the invention:
The purpose of this utility model provides bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four.Invention artificially solves the technical problem that prior art Chinese medicine capsule exists, and reaches the drug effect of treatment, has invented the technical program.
Concrete technical scheme is:
Bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, described capsule is made up of the medicinal mixture and the capsule shells 1 of content, and described capsule shells 1 comprises capsule cap 2, capsule body 3 and sealant 4; Described sealant 4 is arranged in the middle of the capsule shells 1, and described sealant 4 is used for the medicine and the external world are separated.
In the application of reality, be arranged to the sealing coat 5 of rare one deck isolation principal agent and accessory drugs in a side of described capsule sealant 4.
In the application of reality, except the technical scheme that sealing coat is set, can also be provided with at least two combined type cavitys 6 in a side of described capsule sealant 4, described combined type cavity 6 is used to separate different mycopowder, and described combined type cavity 6 is ellipse or circle.
In the application of reality, the thickness of described sealant 4 or sealing coat 5 is: the 0.09-0.10 millimeter.
In the application of reality, described capsule shells 1, sealant 4, sealing coat 5 and combined type cavity 6 by make in the prior art capsular material all can as: gelatin and enteric material are made.
In the application of reality, described capsular being designed to: the length of described capsule cap 2 is between the 7.2-9.8 millimeter; Outer bore is between the 5.32-6.71 millimeter;
The length of described capsule body 3 is between the 12.2-16.6 millimeter; Outer bore is between the 5.05-6.42 millimeter;
Wall thickness is between the 0.09-0.10 millimeter.
In the application of reality, described capsule shells 1 is cylinder or spheroid.
In the application of reality, the strain in the described capsule comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described content particle diameter 2050-70 μ m.
In the application of reality, the content in the described capsule also comprises:
Adjuvants such as sucrose, lactose, microcrystalline Cellulose, modified starch, silicon dioxide, magnesium stearate, Pulvis Talci, HPC.
In the application of reality, be provided with four layers of sealing coat 5 in a side of described capsule sealant 4, described sealing coat 5 is used to separate different mycopowder, and described sealing coat 5 is structure as a whole with capsule shells 1; Fill bacillus bifidus in four layers of sealing coat 5 respectively: 1 * 10
5～1 * 10
9CFU/g, lactobacillus: 1 * 10
5～1 * 10
9CFU/g, enterococcus: 1 * 10
5～1 * 10
9CFU/g, sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described capsular weight is the 20-50 milligram.
This utility model: the capsular production technology of bifidoquater is simple, needn't consider in the production process with excipient such as binding agents; Instantaneous hyperpyrexia and high pressure when simultaneously not having the tablet molding in the bifidoquater capsule manufacture process have been avoided the massive losses (generally will lose the finished product viable count in the tabletting process 5～10 times) of the viable count in the production process, greatly reduce cost; In addition, for activity and the drug effect that guarantees medicine, the technical program has adopted architectural features such as sealant, sealing coat or combined type cavity.
The bifidoquater capsule is an enteric coated capsule, in intestinal or the disintegrate of colon position, avoid of the injury of the gastric acid of gastric juice to viable bacteria, can referring to document " Liu Wenzuo, Qu Xiangkun. the survival rate examination of bacillus bifidus in simulated gastric fluid. Chinese microecology magazine .1997 9 (4) 22 " (seeing Table); Though and tablet can be made enteric solubility, in the process of preparation enteric coating, it is a lot of that viable count is descended, far away from enteric coated capsule optimization.
Table
| Bifidobacterium preparations | Batch number | Conventional sense viable count CFU/ g | Survey viable count CFU/g in the simulated gastric fluid | Survival rate in the simulated gastric fluid | Detect the date |
| Return of spring rubber capsule | 970311 | 18.50 hundred million | 0.037 hundred million | 2.00％ | 97.3.19 |
| Return of spring rubber capsule | 970105 | 13.40 hundred million | 0.022 hundred million | 1.67％ | 97.1.8 |
| The bacillus bifidus mycopowder | 970102 | 733.5 hundred million | 0.040 hundred million | 0.55％ | 97.1.8 |
| Beautiful pearl intestinal is happy | 961039 | 0.075 hundred million | Do not detect viable bacteria | 97.3.19 |
Description of drawings:
Fig. 1 is the sketch map that contains insulation layer structure of the present utility model;
Fig. 2 is the horizontal section sketch map that contains insulation layer structure of the present utility model;
Fig. 3 is the sketch map that contains the combined type cavity body structure of the present utility model.Wherein, 1 is capsule shells; 2 is capsule cap; 3 is capsule body; 4 is sealant; 5 is sealing coat; 6 is the combined type cavity.
Below in conjunction with concrete embodiment accompanying drawing is specifically described.
The specific embodiment:
Embodiment 1:
Fig. 1 is the sketch map that contains insulation layer structure of the present utility model;
Fig. 2 is the horizontal section sketch map that contains insulation layer structure of the present utility model.
Bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, described capsule is made up of the medicinal mixture and the capsule shells 1 of content, and described capsule shells 1 comprises capsule cap 2, capsule body 3 and sealant 4; Described capsule shells 1 is cylinder or spheroid.Described sealant 4 is arranged in the middle of the capsule shells 1, and described sealant 4 is used for the medicine and the external world are separated.And the side at described capsule sealant 4 is arranged to rare four layers of sealing coat 5 of isolating principal agent and accessory drugs.
The thickness of described sealant 4 and sealing coat 5 is: the 0.09-0.10 millimeter.Described capsule shells 1, sealant 4, sealing coat 5 all can be made as gelatin and suitable enteric material by making capsular material in the prior art.
The length of described capsular capsule cap 2 is between the 7.2-9.8 millimeter; Outer bore is between the 5.32-6.71 millimeter; The length of described capsule body 3 is between the 12.2-16.6 millimeter; Outer bore is between the 5.05-6.42 millimeter; Wall thickness is between the 0.09-0.10 millimeter.
Described four layers of sealing coat 5 are used to separate different mycopowder, and described sealing coat 5 is an overall structure with capsule shells 1; The strain of filling respectively in four layers of sealing coat 5 comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described content particle diameter 2050-70 μ m.
Content in the described capsule also comprises: adjuvants such as sucrose, lactose, microcrystalline Cellulose, modified starch, silicon dioxide, magnesium stearate, Pulvis Talci, HPC.Described capsular weight is the 20-50 milligram.
Embodiment 2:
Fig. 3 is the sketch map that contains the combined type cavity body structure of the present utility model;
Bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, described capsule is made up of the medicinal mixture and the capsule shells 1 of content, it is characterized in that: described capsule shells 1 comprises capsule cap 2, capsule body 3 and sealant 4, and described capsule shells 1 is cylinder or spheroid.Described sealant 4 is arranged in the middle of the capsule shells 1, and described sealant 4 is used for the medicine and the external world are separated.
Side at described capsule sealant 4 is provided with two combined type cavitys 6 at least, and described combined type cavity 6 is used to separate different mycopowder, and described combined type cavity 6 is ellipse or circle.
In the application of reality, the thickness of described sealant 4 is: the 0.09-0.10 millimeter.
In the application of reality, described capsule shells 1, sealant 4 and combined type cavity 6 all can be made as gelatin and suitable enteric material by making capsular material in the prior art.
Described capsular being designed to: the length of described capsule cap 2 is between the 7.2-9.8 millimeter; Outer bore is between the 5.32-6.71 millimeter; The length of described capsule body 3 is between the 12.2-16.6 millimeter; Outer bore is between the 5.05-6.42 millimeter; Wall thickness is between the 0.09-0.10 millimeter.
In the application of reality, described two combined type cavitys 6, described combined type cavity 6 is used to separate different mycopowder, and described combined type cavity 6 is an ellipse; The strain of filling in each combined type cavity 6 comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described content particle diameter 2050-70 μ m.
In the application of reality, the content in the described capsule also comprises:
Adjuvants such as sucrose, lactose, microcrystalline Cellulose, modified starch, silicon dioxide, magnesium stearate, Pulvis Talci, HPC.Described capsular weight is the 20-50 milligram.
Claims (10)
1, bacillus bifidus, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, described capsule is made up of the medicinal mixture and the carrier capsule shells of content, it is characterized in that: described capsule shells (1) comprises capsule cap (2), capsule body (3) and sealant (4); Described sealant (4) is arranged in the middle of the capsule shells (1).
2, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four is characterized in that: the side at described capsule sealant (4) is arranged to the sealing coat (5) that rare one deck is isolated principal agent and accessory drugs.
3, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, it is characterized in that: the side at described capsule sealant (4) is provided with at least two combined type cavitys (6), and described combined type cavity (6) is used to separate different mycopowder.
4, bacillus bifidus according to claim 1 and 2, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four is characterized in that: the thickness of described sealant (4) or sealing coat (5) is: the 0.09-0.10 millimeter.
5, according to the described bacillus bifidus of one of claim 1-3, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, it is characterized in that: described capsule shells (1), sealant (4), sealing coat (5) and combined type cavity (6) are made by gelatin and enteric material.
6, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four is characterized in that: the length of described capsule cap (2) is between the 7.2-9.8 millimeter; Outer bore is between the 5.32-6.71 millimeter;
The length of described capsule body (3) is between the 12.2-16.6 millimeter; Outer bore is between the 5.05-6.42 millimeter;
Wall thickness is between the 0.09-0.10 millimeter.
7, according to claim 1 or 3 described bacillus bifiduss, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four, it is characterized in that: described capsule shells (1) is cylinder or spheroid, and described combined type cavity (6) is ellipse or circle.
8, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four is characterized in that: the strain in the described capsule comprises:
Bacillus bifidus: 1 * 10
5～1 * 10
9CFU/g;
Lactobacillus: 1 * 10
5～1 * 10
9CFU/g;
Enterococcus: 1 * 10
5～1 * 10
9CFU/g;
Sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described content particle diameter 2050-70 μ m.
9, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four is characterized in that: the content in the described capsule also comprises:
Sucrose, lactose, microcrystalline Cellulose, modified starch, silicon dioxide, magnesium stearate, Pulvis Talci, HPC adjuvant.
10, bacillus bifidus according to claim 1, lactobacillus, enterococcus, Wax Kind Bacilli Viable Bacteria Capsule of Block of Four is characterized in that:
Side at described capsule sealant (4) is provided with four layers of sealing coat (5), and described sealing coat (5) is used to separate different mycopowder, and described sealing coat (5) is structure as a whole with capsule shells (1); Fill bacillus bifidus in four layers of sealing coat (5) respectively: 1 * 10
5～1 * 10
9CFU/g, lactobacillus: 1 * 10
5～1 * 10
9CFU/g, enterococcus: 1 * 10
5～1 * 10
9CFU/g, sporeformer: 1 * 10
5～1 * 10
9CFU/g;
Described capsular weight is the 20-50 milligram.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2004200662494U CN2732243Y (en) | 2004-06-25 | 2004-06-25 | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2004200662494U CN2732243Y (en) | 2004-06-25 | 2004-06-25 | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN2732243Y true CN2732243Y (en) | 2005-10-12 |
Family
ID=35068090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2004200662494U Expired - Fee Related CN2732243Y (en) | 2004-06-25 | 2004-06-25 | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN2732243Y (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874812B (en) * | 2010-05-14 | 2012-05-23 | 薛恒平 | Composite bacteria preparation and application thereof in weight increment of immature livestock and control of diarrhea |
| CN113116939A (en) * | 2019-12-31 | 2021-07-16 | 杭州远大生物制药有限公司 | Microbial preparation and preparation method thereof |
-
2004
- 2004-06-25 CN CNU2004200662494U patent/CN2732243Y/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874812B (en) * | 2010-05-14 | 2012-05-23 | 薛恒平 | Composite bacteria preparation and application thereof in weight increment of immature livestock and control of diarrhea |
| CN113116939A (en) * | 2019-12-31 | 2021-07-16 | 杭州远大生物制药有限公司 | Microbial preparation and preparation method thereof |
| CN113116939B (en) * | 2019-12-31 | 2023-07-25 | 杭州远大生物制药有限公司 | Microbial preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7249377B2 (en) | bacterial composition | |
| CN1037933C (en) | Coated solid medicament form having releasability in large intestine | |
| CN1480528A (en) | Bifidobacterium and products contg same | |
| CN1289084C (en) | Pharmaceutical formulation | |
| CN1956724A (en) | Oral form of administration containing probiotic bacteria | |
| CN104519866A (en) | Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections | |
| KR20190000937A (en) | Prebiotic formulations and methods of use | |
| CN1211189A (en) | Urogenital and intestinal disorder compositions comprising a substrance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor | |
| US20170100442A1 (en) | Bi-layer dual release probiotic tablets | |
| CN104870002B (en) | For preventing and/or the chitin for treating parasitic disease or derivatives thereof | |
| US11337926B2 (en) | Colon-targeted composition of biological active component and application thereof | |
| US11628192B2 (en) | Bacteroides fragilis for relieving endotoxin infection and application thereof | |
| CN1964722A (en) | Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies | |
| CN2732243Y (en) | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule | |
| US20080118482A1 (en) | Treating mouth ulcer with live bacteria | |
| CN109497560B (en) | Probiotic composition | |
| CN113230284B (en) | Synbiotic microencapsulated preparation based on multi-dimensional crosslinking and preparation method and application thereof | |
| WO2022001673A1 (en) | Novel use of n-acetyl-d-glucosamine and related product | |
| EP1072258A1 (en) | Capsule for the release of bacteria, containing lyophilised bacteria and a method for the production thereof | |
| CN1698669A (en) | Preparation of pinellia decoction for purging stomach fire, its preparing method and application | |
| MX2008015487A (en) | Process for making multiparticulates using a roller compactor. | |
| CN2732244Y (en) | Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite dispersible agent | |
| CN1739504A (en) | L-ornidazole prepn | |
| CN103720674B (en) | Famotidine floating-adhesive micro-tablet capsule and preparation method thereof | |
| US20180339003A1 (en) | Parenteral delivery device and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Assignor: Liu Wei Contract fulfillment period: 2008.8.25 to 2014.6.25 Contract record no.: 2008330001754 Denomination of utility model: Live Bifidobacterium, Lactobacillus, Enterococcus and Bacillus ceresu composite capsule Granted publication date: 20051012 License type: Exclusive license Record date: 20081106 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.8.25 TO 2014.6.25; CHANGE OF CONTRACT Name of requester: HANGZHOU LONGDA XINKE BIOPHARMACEUTICAL CO., LTD. Effective date: 20081106 |
|
| ASS | Succession or assignment of patent right |
Owner name: HANGZHOU LONGDA XINKE BIOLOGY PHARMACEUTICAL CO., Free format text: FORMER OWNER: LIU WEI Effective date: 20100528 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310005 ROOM 6-503, XINYIFANG RESIDENTIAL QUATER, MOGANSHAN ROAD, HANGZHOU CITY, ZHEJIANG PROVINCE TO: 310019 NO.63, JIUHUAN ROAD, JIANGGAN SCIENCE AND TECHNOLOGY ECONOMIC PARK, HANGZHOU CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100528 Address after: 310019, No. nine, 63 Ring Road, Jianggan science and Technology Economic Zone, Hangzhou Patentee after: HANGZHOU LONGDA XINKE BIOLOGICAL PHARMACEUTICAL CO., LTD. Address before: Hangzhou City, Zhejiang province 310005 Moganshan Road, district 6-503 room Patentee before: Liu Wei |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051012 Termination date: 20110625 |